Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling

DOI10.4310/SII.2018.V11.N1.A10MaRDI QIDQ1782097zbMATH OpenOpenAlexFDO

Authors Yang Yang, Hong-Bin Fang, Anindya Roy, Ming Tan

Publication date 18 September 2018

Published in Statistics and Its Interface (Search for Journal in Brave)

Full work available at URL https://doi.org/10.4310/sii.2018.v11.n1.a10

zbMATH Keywords

objective functiondrug combinationdose findingadaptive Bayesian designBliss independenceinteraction index functionmaximum tolerated dose (MTD)maximum tolerated region

Mathematics Subject Classification ID

Statistics (62-XX)

Recommendations

• Adaptive clinical trial designs for phase I cancer studies
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Adaptive designs for drug combination informed by longitudinal model for the response
• Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
• A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents

Cited in

(3)

• A multi‐source adaptive platform design for testing sequential combinatorial therapeutic strategies
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• Design and modeling for drug combination experiments with order effects

This page was built for publication: Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1782097)